1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013.PubMed/NCBI View Article : Google Scholar
|
2
|
Cancer Research UK: Pancreatic Cancer
Mortality Statistics. Available from: urihttp://www.cancerresearchuk.org/cancer-info/cancerstats/types/pancreas/mortality/simplehttp://www.cancerresearchuk.org/cancer-info/cancerstats/types/pancreas/mortality/.
|
3
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Eng J Med. 364:1817–1825.
2011.PubMed/NCBI View Article : Google Scholar
|
4
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013.PubMed/NCBI View Article : Google Scholar
|
5
|
Nagakawa T, Kurachi M, Konishi K and
Miyazaki I: Translateral retroperitoneal approach in radical
surgery for pancreatic carcinoma. Jpn J Surg. 12:229–233.
1982.PubMed/NCBI View Article : Google Scholar
|
6
|
Nagakawa T, Nagamori M, Futakami F,
Tsukioka Y, Kayahara M, Ohta T, Ueno K and Miyazaki I: Result of
extensive surgery for pancreatic carcinoma. Cancer. 77:640–645.
1996.PubMed/NCBI
|
7
|
Kitagawa H, Tajima H, Nakagawara H, Makino
I, Miyashita T, Shoji M, Nakanuma S, Hayashi N, Takamura H, Ohta T
and Ohtake H: En bloc vascular resection for the treatment of
borderline resectable pancreatic head carcinoma. Mol Clin Oncol.
2:369–374. 2014.PubMed/NCBI View Article : Google Scholar
|
8
|
Evans DB, Abbruzzese JL and Willett CG:
Cancer of the pancreas. In: Cancer: Priciples and Practice of
Oncology (6th edition). DeVita VT, Hellman S and Rosenberg SA
(eds). Lippincott Williams and Wilkins, Philadelphia, PA,
pp1126-1161, 2001.
|
9
|
Ottle H, Post S, Neuhaus P, Gellert K,
Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C,
et al: Adjuvant chemotherapy with gemcitabine vs observation in
patients undergoing curative-intent resection of pancreatic cancer:
A randomized controlled trial. JAMA. 297:267–277. 2007.PubMed/NCBI View Article : Google Scholar
|
10
|
Uesaka K, Boku N, Fukutomi A, Okamura Y,
Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto
H, et al: Adjuvant chemotherapy of S-1 versus gemcitabine for
resected pancreatic cancer: A phase 3, open-label, randomized,
non-inferiority trial (JASPAC 01). Lancet. 388:248–257.
2016.PubMed/NCBI View Article : Google Scholar
|
11
|
Klinlenbijl JH, Jeekel J, Sahmoud T, van
Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, de Wit LT,
Hennipman A and Wils J: Adjuvant radiotherapy and 5-fluorouracil
after curative resection of cancer of the pancreas and
periampullary region: Phase III trial of the EORTC gastrointestinal
tract cancer cooperative group. Ann Surg. 230:776–784.
1999.PubMed/NCBI View Article : Google Scholar
|
12
|
Spitz FR, Abbruzzese JL, Lee JE, Pisters
PW, Lowy AM, Fenoglio CJ, Cleary KR, Janjan NA, Goswitz MS, Rich TA
and Evans DB: Preoperative and postoperative chemoradiation
strategies in patients treated with pancreaticoduodenectomy for
adenocarcinoma of the pancreas. J Clin Oncol. 15:928–937.
1997.PubMed/NCBI View Article : Google Scholar
|
13
|
Yeo CJ, Abrams RA, Grochow LB, Sohn TA,
Ord SE, Hruban RH, Zahurak ML, Dooley WC, Coleman J, Sauter PK, et
al: Pancreaticoduodenectomy for pancreatic adenocarcinoma:
Postoperative adjuvant chemoradiation improves survival. A
prospective, single-institution experience. Ann Surg. 225:621–636.
1997.PubMed/NCBI View Article : Google Scholar
|
14
|
Tajima H, Ohta T, Kitagawa H, Okamoto K,
Sakai S, Makino I, Kinoshita J, Furukawa H, Nakamura K, Hayashi H,
et al: Pilot study of neoadjuvant chemotherapy with gemcitabine and
oral S-1 for resectable pancreatic cancer. Exp Therap Med.
3:787–792. 2012.PubMed/NCBI View Article : Google Scholar
|
15
|
Katz MH, Shi Q, Ahmad SA, Herman JM, Marsh
Rde W, Collisson E, Schwartz L, Frankel W, Martin R, Conway W, et
al: Preoperative modified FOLFIRINOX treatment followed by
capecitabine-based chemoradiation for borderline resectable
pancreatic cancer: Alliance for clinical trials in oncology Trial
A021101. JAMA Surg. 151(e161137)2016.PubMed/NCBI View Article : Google Scholar
|
16
|
Shubert CR, Bergquist JR, Groeschl RT,
Habermann EB, Wilson PM, Truty MJ, Smoot RL, Kendrick ML, Nagorney
DM and Farnell MB: Overall survival is increased among stage III
pancreatic adenocarcinoma patients receiving neoadjuvant
chemotherapy compared to surgery first and adjuvant chemotherapy:
An intention to treat analysis of the National cancer database.
Surgery. 160:1080–1096. 2016.PubMed/NCBI View Article : Google Scholar
|
17
|
Nagakawa Y, Hosokawa Y, Nakayama H, Sahara
Y, Takishita C, Nakajima T, Hijikata Y, Kasuya K, Katsumata K,
Tokuuye K and Tsuchida A: A phase II trial of neoadjuvant
chemoradiotherapy with intensity-modulated radiotherapy combined
with gemcitabine and S-1 for borderline-resectable pancreatic
cancer with arterial involvement. Cancer Chemother Pharmacol.
79:951–957. 2017.PubMed/NCBI View Article : Google Scholar
|
18
|
Ettrich TJ, Berger AW, Perkhofer L, Daum
S, König A, Dickhut A, Wittel U, Wille K, Geissler M, Algül H, et
al: Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus
gemcitabine for resectable pancreatic cancer-the NEONAX trial
(AIO-PAK-0313), a prospective, randomized, controlled, phase II
study of the AIO pancreatic cancer group. BMC Cancer.
18(1298)2018.PubMed/NCBI View Article : Google Scholar
|
19
|
Tajima H, Ohta T, Okazaki M, Yamaguchi T,
Ohbatake Y, Okamoto K, Nakanuma S, Kinoshita J, Makino I, Nakamura
K, et al: Neoadjuvant chemotherapy with gemcitabine-based regimens
improves prognosis of node positive resectable pancreatic head
cancer. Mol Clinic Oncol. 11:157–166. 2019.PubMed/NCBI View Article : Google Scholar
|
20
|
Common Terminology Criteria for Adverse
Event (CTCAE) Version 4.0. Department of Health and Human Services,
National Institutes of Health, National Cancer Institute, May 28,
2009.
|
21
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumors:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009.PubMed/NCBI View Article : Google Scholar
|
22
|
Dino D, Demartines N and Clavian PA:
Classification of surgical complications: A new proposal with
evaluation in a cohort of 6336 patients and results lf a survey.
Ann Surg. 240:205–213. 2004.PubMed/NCBI View Article : Google Scholar
|
23
|
Makino I, Kitagawa H, Ohta T, Nakagawara
H, Tajima H, Ohnishi I, Takamura H, Tani T and Kayahara M: Nerve
plexus invasion in pancreatic cancer: Spread patterns on
histopathologic and embryological analysis. Pancreas. 37:358–365.
2008.PubMed/NCBI View Article : Google Scholar
|
24
|
Classification of Pancreatic Carcinoma
(Fourth English Edition). Japan Pancreas Society, Kanehara &
Co., Ltd., 2017.
|
25
|
Bassi C, Marchegiani G, Dervenis C, Sarr
M, Abu Hilal M, Adham M, Allen P, Andersson R, Asbun HJ, Besselink
MG, et al: The 2016 update of the international study group (ISGPS)
definition and grading of postoperative pancreatic fistula: 11
years after. Surgery. 161:584–591. 2017.PubMed/NCBI View Article : Google Scholar
|
26
|
National Comprehensive Cancer Network:
Practice guidelines in oncology for pancreatic adenocarcinoma
version 1.2020, 2019.
|
27
|
Tajima H, Kitagawa H, Tsukada T, Nakanuma
S, Okamoto K, Sakai S, Makino I, Furukawa H, Nakamura K, Hayashi H,
et al: A phase I study of neoadjuvant chemotherapy with gemcitabine
plus oral S-1 for resectable pancreatic cancer. Mol Clinic Oncol.
1:768–772. 2013.PubMed/NCBI View Article : Google Scholar
|
28
|
Motoi F, Kosuge T, Ueno H, Yamaue H, Satoi
S, Sho M, Honda G, Matsumoto I, Wada K, Furuse J, et al: Randomized
phase II/III trial of neoadjuvant chemotherapy with gemcitabine and
S-1 versus upfront surgery for resectable pancreatic cancer
(Prep-02/JSAP05). Jpn J Clin Oncol. 49:190–194. 2019.PubMed/NCBI View Article : Google Scholar
|
29
|
Miyasaka Y, Ohtsuka T, Kimura R, Matsuda
R, Mori Y, Nakata K, Kakihara D, Fujimori N, Ohno T, Oda Y and
Nakamura M: Neoadjuvant chemotherapy with gemcitabine plus
nab-paclitaxel for borderline resectable pancreatic cancer
potentially improves survival and facilitates surgery. Ann Surg
Oncol. 26:1528–1534. 2019.PubMed/NCBI View Article : Google Scholar
|
30
|
Macedo FI, Ryon E, Maithel SK, Lee RM,
Kooby DA, Fields RC, Hawkins WG, Williams G, Maduekwe U, Kim HJ, et
al: Survival outcomes associated with clinical and pathological
response following neoadjuvant FOLFIRINOX or
gemcitabine/nab-paclitaxel chemotherapy in resected pancreatic
cancer. Ann Surg. 270:400–413. 2019.PubMed/NCBI View Article : Google Scholar
|
31
|
Okada K, Hirono S, Kawai M, Miyazawa M,
Shimizu A, Kitahata Y, Ueno M, Hayami S and Yamaue H: Phase I study
of Nab-Paclitaxel plus gemcitabine as neoadjuvant therapy for
borderline resectable pancreatic cancer. Anticancer Res.
37:853–858. 2017.PubMed/NCBI View Article : Google Scholar
|
32
|
Valle S, Martin-Hijano L, Alcalá S,
Alonso-Nocelo M and Sainz B Jr: The ever-evolving concept of the
cancer stem cell in pancreatic cancer. Cancers (Basel).
10(33)2018.PubMed/NCBI View Article : Google Scholar
|
33
|
Zhang D, Sun L, Xian W, Liu F, Ling G,
Xiao L, Liu Y, Peng Y, Haruna Y and Kanwar YS: Low-dose paclitaxel
ameliorates renal fibrosis in rat UUO model by inhibition of
TGF-beta/Smad activity. Lab Invest. 90:436–447. 2010.PubMed/NCBI View Article : Google Scholar
|
34
|
Zhou J, Zhong DW, Wang QW, Miao XY and Xu
XD: Paclitaxel ameliorates fibrosis in hepatic stellate cells via
inhibition of TGF-beta/Smad activity. World J Gastroenterol.
16:3330–3334. 2010.PubMed/NCBI View Article : Google Scholar
|
35
|
Choi HS, Savard CE, Choi JW, Kuver R and
Lee SP: Paclitaxel interrupts TGF-beta1 signaling between
gallbladder epithelial cells and myofibroblasts. J Surg Res.
141:183–191. 2007.PubMed/NCBI View Article : Google Scholar
|
36
|
Hirose A, Tajima H, Ohta T, Tsukada T,
Okamoto K, Nakanuma S, Sakai S, Kinoshita J, Makino I, Furukawa H,
et al: Low-dose paclitaxel inhibits the induction of
epidermal-mesenchymal transition in the human cholangiocarcinoma
CCKS-1 cell line. Oncol Lett. 6:915–920. 2013.PubMed/NCBI View Article : Google Scholar
|
37
|
Miyashita T, Tajima H, Makino I, Okazaki
M, Yamaguchi T, Ohbatake Y, Nakanuma S, Hayashi H, Takamura H,
Ninomiya I, et al: Neoadjuvant chemotherapy with gemcitabine plus
Nab-paclitaxel reduces the number of cancer-associated fibroblasts
through depletion of pancreatic stroma. Anticancer Res. 38:337–343.
2018.PubMed/NCBI View Article : Google Scholar
|
38
|
Chan KKW, Guo H, Cheng S, Beca JM,
Redmond-Misner R, Isaranuwatchai W, Qiao L, Earle C, Berry SR,
Biagi JJ, et al: Real-world outcomes of FOLFIRINOX vs gemcitabine
and nab-paclitaxel in advanced pancreatic cancer: A
population-based propensity score-weighted analysis. Cancer Med.
9:160–169. 2020.PubMed/NCBI View Article : Google Scholar
|
39
|
Dhir M, Zenati MS, Hamad A, Singhi AD,
Bahary N, Hogg ME, Zeh HJ III and Zureikat AH: FOLFIRINOX versus
gemcitabine/nab-paclitaxel for neoadjuvant treatment of resectable
and borderline resectable pancreatic head adenocarcinoma. Ann Surg
Oncol. 25:1896–1903. 2018.PubMed/NCBI View Article : Google Scholar
|
40
|
Polistina F, Di Natale G, Bonciarelli G,
Ambfosino G and Frego M: Neoadjuvant strategies for pancreatic
cancer. World J Gastroenterol. 20:9374–9383. 2014.PubMed/NCBI View Article : Google Scholar
|
41
|
Gillen S, Schuster T, Meyer Zum
Büschenfelde C, Friess H and Kleeff J: Preoperative/neoadjuvant
therapy in pancreatic cancer: A systemic review and meta-analysis
of response and resection percentages. PLoS Med.
7(e1000267)2010.PubMed/NCBI View Article : Google Scholar
|
42
|
Silvestris N, Brunetti O, Vasile E,
Cellini F, Cataldo I, Pusceddu V, Cattaneo M, Partelli S, Scartozzi
M, Aprile G, et al: Multimodal treatment of resectable pancreatic
ductal adenocarcinoma. Crit Rev Oncol Hematol. 111:152–165.
2017.PubMed/NCBI View Article : Google Scholar
|
43
|
Nakayama A, Ninomiya I, Harada S, Tsukada
T, Okamoto K, Nakanuma S, Sakai S, Makino I, Kinoshita J, Hayashi
H, et al: Metformin inhibits the radiation-induced invasive
phenotype of esophageal squamous cell carcinoma. Int J Oncol.
49:1890–1898. 2016.PubMed/NCBI View Article : Google Scholar
|
44
|
Van Laethem JL, Hammel P, Mornex F, Azria
D, Van Tienhoven G, Vergauwe P, Peeters M, Polus M, Praet M, Mauer
M, et al: Adjuvant gemcitabine alone versus gemcitabine-based
chemoradiotherapy after curative resection for pancreatic cancer: A
randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J
Clin Oncol. 28:4450–4456. 2010.PubMed/NCBI View Article : Google Scholar
|
45
|
Mochizuki K, Gabata T, Kozaka K, Hattori
Y, Zen Y, Kitagawa H, Kayahara M, Ohta T and Matsui O: MDCT
findings of extrapancreatic nerve plexus invasion by pancreas head
carcinoma: Correlation with en bloc pathological specimens and
diagnostic accuracy. Eur Radiol. 20:1757–1767. 2010.PubMed/NCBI View Article : Google Scholar
|